References
- Pharmrig facts and figures 2001. Medication and health care in Austria.
- Cost to treat a depression case falls: Bigger share of sufferers are now receiving help, so total expenditures rise. http://www.mindfully.org/Health/2003/ Depression-Cost-Bigger31dec03.htm (accessed 17th May 2004).
- Lenox-Smith A, Conway P, Knight C. Cost effectiveness of representatives of three classes of antidepressants used in major depression in the UK. Pharmacoeconomics 2004; 22: 311–319.
- Freeman H, Arikian S, Lenox-Smith A. Pharmacoeconomic analysis of antidepressants for major depressive disorder in the UK. Pharmacoeconomics 2000; 18: 143–148.
- Thase ME, Entusah RA, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. British Journal of Psychiatry 2001; 178: 234–241.
- Einarson TR, Arikian S, Sweeney S, Doyle J. A model to evaluate the cost- effectiveness of oral therapies in the management of patients with major depressive disorder. Clinical Therapeutics 1995; 17: 136–153.
- Clerc GE, Ruimy P, Verdeau-Pailles J et al. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. International Clinical Psychopharmacotherapy 1994; 9: 139–143.
- Dierick M, Ravizza L, Realini R et al. A double blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Progress in Neuropsychopharmacology and Biological Psychiatry 1996; 20: 57–71.
- Rudolph RL, Entsuah R, Aguiar L et al. Early onset of antidepressant activity of venlafaxine compared with placebo and fluoxetine in outpatients in a double-blind study European Neuropsychopharmacology 1998; 8 (Suppl 2): S142.
- Rudolph RL, Feiger AD. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. Journal of Affective Disorders 1999; 56: 171–181.
- Salinas E, for the Venlafaxine XR 367 Study Group. Once-daily extended release (XR) venlafaxine versus paroxetine in outpatients with major depression. Biological Psychiatry 1997; 42 (Suppl 1): 244S.
- Silverstone PH, Ravindran A, for the Venlafaxine XR 360 Study Group. Once- daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Journal of Clinical Psychiatry 1999; 60: 22–28.
- Doyle JJ, Casciano J, Arikian S et al. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost- effectiveness between venlafaxine, SSRIs, and TCAs. Value in Health 2001; 4: 16–31.
- Casciano J, Doyle J, Arikian S, Casciano R. The health economic impact of antidepressant utilization from a payer’s perspective: a multinational study. International Journal of Clinical Practice 2001; 55: 292–299.
- Kelsey JE. Treatment strategies in achieving remission in major depressive disorder. Acta Psychiatrica Scandinavica Supplementum 2002; 415: 18–23.